Triptans: Low utilization and high turnover in the general population
- 1 October 2009
- journal article
- Published by SAGE Publications in Cephalalgia
- Vol. 30 (5), 576-581
- https://doi.org/10.1111/j.1468-2982.2009.02001.x
Abstract
Studies performed in selected populations have shown a poor utilization of triptans for migraine. Our study was aimed at establishing patterns of triptans utilization in a large community using the pharmaceutical prescriptions database of two consecutive years in a regional Health Authority in Italy. About 0.5% of the population observed received triptans prescriptions in a year, but > 50% of the cases received only one prescription. On the other hand, 46% of triptan users did not receive a triptan prescription in the following year (past users): in 80% of cases, patients received only 1–2 triptan packages. The evaluation of the discontinued triptan type has shown percentages varying between 30 and 70%. The percentage of triptan users who received a triptan prescription for the first time in the successive year of study (new users) was 52%. These findings together highlight a high turnover in triptans utilization. Less than 15% of subjects received more than one triptan product in the 2 years. In conclusion, we observed a low percentage of triptan users and a low rate of utilization, associated with a high percentage of discontinuation and new utilization (high turnover), without any substantial increase in triptans utilization during the years. All these data probably do not support optimal satisfaction with triptan therapy.Keywords
This publication has 30 references indexed in Scilit:
- Triptans in the Italian population: a drug utilization study and a literature reviewThe Journal of Headache and Pain, 2008
- Patterns of Triptans Use: A Study Based on the Records of a Community Pharmaceutical DepartmentCephalalgia, 2007
- The Global Burden of Headache: A Documentation of Headache Prevalence and Disability WorldwideCephalalgia, 2007
- Crossover, double‐blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapyEuropean Journal of Neurology, 2007
- Infrequent or Non-Response to Oral Sumatriptan does not Predict Response to Other Triptans—Review of Four TrialsCephalalgia, 2006
- Patients’ preference for triptans and other medications as a tool for assessing the efficacy of acute treatments for migraineThe Journal of Headache and Pain, 2005
- Triptan Nonresponder Studies: Implications for Clinical PracticeHeadache: The Journal of Head and Face Pain, 2005
- Double-Blind Clinical Trials of Oral Triptans Vs Other Classes of Acute Migraine Medication — A ReviewCephalalgia, 2004
- Migraine Prevalence and Treatment Patterns: The Global Migraine and Zolmitriptan Evaluation SurveyHeadache: The Journal of Head and Face Pain, 2003
- Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trialsThe Lancet, 2001